AR and prostate carcinoma: In the context of prostate cancer, the CRISP3 promoter is regulated by the androgen receptor (AR) through an epigenetic mechanism, and CRISP3 expression is induced by the presence of dihydrotestosterone (DHT) in AR-positive cells.